Side Effects of emtricitabine and tenofovir: A Synthesis of Findings from 27 Studies

  1. Home
  2. Side Effects of emtricitabine and tenofovir
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of emtricitabine and tenofovir: A Synthesis of Findings from 27 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of emtricitabine and tenofovir: A Synthesis of Findings from 27 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Emtricitabine and tenofovir combination is a widely used drug for treating HIV-infected individuals. Many studies have confirmed that this combination is highly effective and safe. 4 is a study that compared emtricitabine/tenofovir combination with efavirenz/emtricitabine/tenofovir combination, and it showed that emtricitabine/tenofovir combination had fewer side effects and was better tolerated.

On the other hand, 2 compared emtricitabine/tenofovir combination with raltegravir, atazanavir/ritonavir, and darunavir/ritonavir, respectively. As a result, it showed that when combined with raltegravir, it was superior to other combinations in terms of both efficacy and tolerability.

8 evaluated the efficacy and safety of emtricitabine/tenofovir alafenamide combination (Genvoya). This study suggests that emtricitabine/tenofovir alafenamide combination has fewer side effects such as renal function, bone density, and metabolic effects compared to tenofovir disoproxil fumarate combination.

20 compared the effects on renal function of emtricitabine/tenofovir alafenamide combination and dolutegravir/abacavir/lamivudine combination. This study states that neither combination had a significant impact on renal function.

Also, 24 reported the results of a survey on the awareness and use of PrEP (pre-exposure prophylaxis) among men who have sex with men in China. The survey results showed that emtricitabine/tenofovir combination was most commonly used as PrEP, and factors related to its use included age, monthly income, experience of unprotected anal sex in the past year, use of sexual drugs, and diagnosis of sexually transmitted diseases.

These studies show that emtricitabine/tenofovir combination is a highly effective and safe drug. However, it is not without side effects. In order to minimize side effects, it is important to consult with your doctor and receive proper medication.

Reason for Side Effects

Side effects of emtricitabine/tenofovir combination are thought to be caused by various factors, including the drug's mechanism of action and individual body constitution. As for the mechanism of action of the drug, it is known to affect the kidneys and bones. 8 suggests that emtricitabine/tenofovir alafenamide combination has fewer side effects such as renal function, bone density, and metabolic effects compared to tenofovir disoproxil fumarate combination. This is thought to be because tenofovir alafenamide has less impact on the kidneys and bones compared to tenofovir disoproxil fumarate.

Also, some people are more prone to side effects due to their individual constitution. For example, 4 reported that some patients who took emtricitabine/tenofovir combination experienced side effects such as sleep disturbances and diarrhea. These side effects are thought to be caused by individual differences in susceptibility to the drug.

Common Side Effects

Renal Dysfunction

Renal dysfunction is a possible side effect of emtricitabine/tenofovir combination. Research such as 8 and 20 examined the effects of emtricitabine/tenofovir combination on renal function, but no major effects were found.

Osteoporosis

Emtricitabine/tenofovir combination may increase the risk of osteoporosis. 8 suggests that emtricitabine/tenofovir alafenamide combination has less impact on bone density compared to tenofovir disoproxil fumarate combination. However, the risk of osteoporosis cannot be completely ruled out.

Metabolic Abnormalities

Emtricitabine/tenofovir combination can cause metabolic abnormalities. 8 suggests that emtricitabine/tenofovir alafenamide combination has less impact on metabolism compared to tenofovir disoproxil fumarate combination.

Neurological Symptoms

Neurological symptoms are a possible side effect of emtricitabine/tenofovir combination. 4 and 5 reported that some patients who took emtricitabine/tenofovir combination experienced neurological symptoms such as sleep disturbances, headaches, and dizziness. Also, 7 reported that neurological symptoms improved when switching from efavirenz to emtricitabine/tenofovir alafenamide combination.

Gastrointestinal Symptoms

Gastrointestinal symptoms are a possible side effect of emtricitabine/tenofovir combination. 4 reported that some patients who took emtricitabine/tenofovir combination experienced gastrointestinal symptoms such as diarrhea and nausea.

Others

Other symptoms have also been reported as side effects of emtricitabine/tenofovir combination. 1 reported that vitamin D levels increased when switching from emtricitabine/tenofovir combination to darunavir/ritonavir. Also, 9 reported that some patients who took emtricitabine/tenofovir combination showed decreased mitochondrial function.

Countermeasures for Side Effects

Countermeasures for Renal Dysfunction

To prevent renal dysfunction, it is important to regularly check your blood to monitor your renal function. If your renal function is impaired, you may need to adjust your dosage or switch to another drug under the guidance of your doctor.

Countermeasures for Osteoporosis

To prevent osteoporosis, it is important to consume sufficient amounts of calcium and vitamin D. It is also important to regularly check your bone density to monitor the condition of your bones.

Countermeasures for Metabolic Abnormalities

To prevent metabolic abnormalities, diet and exercise are important. Avoid high-fat and high-calorie foods and engage in moderate exercise. It is also important to regularly check your blood sugar and lipid levels.

Countermeasures for Neurological Symptoms

If you experience neurological symptoms, consult with your doctor. If necessary, your dosage may be adjusted, or you may need to switch to another drug. Lifestyle changes are also important. Be sure to get enough sleep and avoid stress.

Countermeasures for Gastrointestinal Symptoms

If you experience gastrointestinal symptoms, consult with your doctor. If necessary, your dosage may be adjusted, or you may need to switch to another drug. Diet therapy is also important. Eat easily digestible foods and avoid spicy foods.

Comparison between Studies

Common Points of Studies

Many studies have shown that emtricitabine/tenofovir combination is an effective drug for treating HIV-infected individuals. In addition, many studies have reported side effects such as renal function, bone density, and metabolic effects. However, the severity and frequency of side effects vary across studies.

Differences between Studies

It is difficult to compare the results of studies because the type of emtricitabine/tenofovir combination used, the patient population, and the evaluation criteria differ across studies. For example, 8 evaluated the efficacy and safety of emtricitabine/tenofovir alafenamide combination. On the other hand, 20 compared the effects on renal function of emtricitabine/tenofovir alafenamide combination and dolutegravir/abacavir/lamivudine combination. Because the subjects and evaluation criteria vary across studies, direct comparison is impossible.

Precautions for Application in Real Life

Emtricitabine/tenofovir combination is an effective drug for treating HIV-infected individuals, but it is important to understand the risk of side effects before taking it. While taking the drug, be sure to undergo regular checkups and blood tests as directed by your doctor. If you experience any side effects, consult with your doctor immediately. Do not discontinue the drug or switch to other drugs without consulting your doctor.

Limitations of Current Research

Research on emtricitabine/tenofovir combination is not yet complete. In particular, further research is needed on long-term side effects and differences in side effects between different races and ethnicities.

Future Research Directions

Further research is needed on the long-term side effects of emtricitabine/tenofovir combination and differences in side effects between different races and ethnicities. Also, the development of new drugs and therapies to reduce the side effects of emtricitabine/tenofovir combination is expected.

Conclusion

Emtricitabine/tenofovir combination is an effective drug for treating HIV-infected individuals, but there is a risk of side effects. In order to minimize side effects, it is important to consult with your doctor and receive proper medication. If you experience any side effects, consult with your doctor immediately. Do not discontinue the drug or switch to other drugs without consulting your doctor.

Literature analysis of 27 papers
Positive Content
25
Neutral Content
0
Negative Content
2
Article Type
7
0
0
3
27
1.

Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).

Author: HamzahLisa, TiraboschiJuan M, IvesonHelen, TobyMartina, MantChristine, CasonJohn, BurlingKeith, WandoloEmily, JendrulekIsabelle, TaylorChris, IbrahimFowzia, KulasegaramRanjababu, TeagueAlastair, PostFrank A, FoxJulie

Improved bone density
Increased Vitamin D
Renal dysfunction

This study investigated the potential of switching from fixed-dose tenofovir/emtricitabine/efavirenz to darunavir/ritonavir monotherapy to improve vitamin D levels, bone mineral density, and renal tubular function.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain.

Author: DavisAshley E, BroganAnita J, GoodwinBridgett, NoceaGonzalo, LozanoVirginia

HIV-1 treatment

Raltegravir, when used in combination with emtricitabine/tenofovir DF, demonstrated superior virologic efficacy and tolerability compared to atazanavir/ritonavir and darunavir/ritonavir in treatment-naive adults with HIV-1 infection in a 96-week clinical trial. This study aimed to estimate the efficiency of these three regimens in Spain.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.

Author: WilkinsEd L, CohenCalvin J, TrottierBenoit, EsserStefan, SmithDon E, HaasBernhard, BrinsonCynthia, GarnerWill, ChuckSusan, ThorpeDavid, De-OertelShampa

HIV-1 infection treatment
treatment-emergent adverse events

This 96-week, randomized, open-label study compared the efficacy and safety of two single-tablet regimens for treatment-naïve HIV-1-infected adults: rilpivirine (RPV) + emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and efavirenz (EFV) + FTC/TDF. The study found that both regimens were associated with high adherence, high treatment satisfaction, and improved quality of life. However, RPV/FTC/TDF was associated with fewer treatment-emergent adverse events and patient-reported symptoms.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.

Author: GallienSébastien, FlandrePhilippe, NguyenNga, De CastroNathalie, MolinaJean-Michel, DelaugerreConstance

Virological outcomes
Neurological symptoms

This study compared the clinical outcomes of two antiretroviral therapy (ART) regimens for HIV-1 patients: TDF/FTC+EFV and EFV/FTC/TDF. Results showed similar outcomes between the two groups, suggesting that the single-tablet regimen EFV/FTC/TDF could be approved for initial ART.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.

Author: HodderSally, SquiresKathleen, KityoCissy, HaginsDebbie, AvihingsanonAnchalee, KidoAnna, JiangShuping, KulkarniRima, ChengAndrew, CaoHuyen

Integrase inhibitor efficacy
TAF-based regimen efficacy

This study investigated the efficacy, safety, and tolerability of switching to a TAF-based, single-tablet regimen containing elvitegravir, cobicistat, FTC, and tenofovir alafenamide (E/C/F/TAF) versus remaining on ATV + RTV plus FTC/TDF.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

8.

A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.

Author: AngioneSara A, CherianSibyl M, ÖzdenerAyşe Elif

Manage HIV-1 infection
Bone mineral density loss
Metabolic effects
Renal impairment

This review examines the efficacy and safety of Genvoya®, a single-tablet regimen for HIV-1 infection, comparing it to regimens containing tenofovir disoproxil fumerate (TDF). It explores the impact of Genvoya® on renal impairment, bone mineral density, metabolic effects, and other adverse events.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.

Author: GilmoreHailey J, LiuAlbert, KoesterKimberly Ann, AmicoK Rivet, McMahanVanessa, GoicocheaPedro, VargasLorena, LubenskyDavid, BuchbinderSusan, GrantRobert

PrEP efficacy
Reduced HIV acquisition
Changes in routine
Side effects

High adherence to daily PrEP (emtricitabine/tenofovir disoproxil fumarate) for HIV prevention was linked to established routines, client-centered counseling, and positive relationships with healthcare providers. Future interventions should focus on these aspects to improve adherence.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics.

Author: GiraudJean-Stephane, DoisneMelanie, Chan Hew WaiAurelie, MajerholcCatherine, FournErwan, SejeanKarine, TrichereauJulie, BonanBrigitte, ZucmanDavid

HIV treatment cost reduction

This study aimed to study HIV-infected patients' acceptability to switch from a brand single-tablet regimens to a treatment comprising of two pills: one is a fixed-dose generic combination of 2 Nucleoside Analogs and the second tablet is the third antiretroviral.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

14.

"Free Testing and PrEP without Outing Myself to Parents:" Motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men.

Author: FisherCelia B, FriedAdam L, Ibrahim PuriLeah, MacapagalKathryn, MustanskiBrian

Non-adherence to oral PrEP
Undue influence

Adolescent men who have sex with men (AMSM) are disproportionately affected by HIV. This study examined AMSM attitudes toward participating in oral/injectable PrEP trials to inform ethical protections for youth in future research. Understanding their motivations is crucial to ensure voluntary participation without undue influence.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

15.

Barriers to HIV pre-exposure prophylaxis among African, Caribbean and Black men in Toronto, Canada.

Author: ZhabokritskyAlice, NelsonLaRon E, TharaoWangari, HusbandsWinston, SaTing, ZhangNanhua, Thomas-PavanelJamie, BaidoobonsoShamara, KaulRupert

HIV prevention
Racial disparities

Emtricitabine/tenofovir, a single-pill HIV prevention medication (PrEP), is effective, but usage varies across racial groups. This study highlights the need for specific guidance on implementing PrEP in African, Caribbean, and Black communities who are disproportionately affected by HIV.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.

Author: MayerKenneth H, JonesDaniel, OldenburgCatherine, JainSachin, GelmanMarcy, ZaslowShayne, GrassoChris, MimiagaMatthew J

Higher completion rates
Gastrointestinal side effects

Elvitegravir/cobicistat/TDF/FTC was safe and well tolerated for PEP, with higher regimen completion rates than more frequently dosed PEP regimens.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

18.

Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial.

Author: CorneliAmy, PerryBrian, McKennaKevin, AgotKawango, AhmedKhatija, TaylorJamilah, MalamatshoFulufhelo, OdhiamboJacob, SkhosanaJoseph, Van DammeLut

HIV prevention
Side effects

A follow-up study of 88 former participants in a clinical trial of daily, oral emtricitabine/tenofovir disoproxil fumarate for HIV prevention found that concerns about the study pill and discouragement from others seemed to have significantly influenced nonadherence. Participants reported concerns about the investigational nature of the drug, side effects, and HIV-related stigma.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

19.

High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya.

Author: Van der ElstElisabeth Maria, MboguaJudie, OperarioDon, MutuaGaudensia, KuoCaroline, MugoPeter, KanungiJennifer, SinghSagri, HabererJessica, PriddyFrances, SandersEduard Joachim

HIV prevention
Adherence challenges
Social stigma

A study explored the experiences of men who have sex with men and female sex workers using oral PrEP for HIV prevention in Kenya. PrEP was found to be generally acceptable, with initial side effects improving over time. However, social stigma and challenges with adherence due to daily life complexities, particularly post-coital dosing, were noted. Consistent counseling addressing these issues could improve PrEP's effectiveness.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

20.

Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.

Author: Rotea-SalvoSandra, Martínez-PradedaAlejandro, Fernández-OliveiraCarla, Giménez-ArufeVictor, Balboa-BarreiroVanesa, Margusino-FramiñánLuis, Mena-De-CeaÁlvaro, Vázquez-RodríguezPilar, Castro-IglesiasÁngeles, López-CalvoSoledad, Martín-HerranzIsabel, Míguez-ReyEnrique, Cid-SilvaPurificación

Renal safety
Adverse events

This retrospective observational study evaluated modifications in the renal safety profile of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) in a large real-world cohort of HIV-infected patients. The results showed that serum creatinine improved in both groups among experienced patients, while it remained stable in naive patients. Statistically significant differences in serum creatinine were observed between the two treatment groups, with EVG/c/FTC/TAF showing a lower serum creatinine level.

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

21.

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.

Author: GallantJoel, MoyleGraeme, BerenguerJuan, ShalitPeter, CaoHuyen, LiuYa-Pei, MyersJoel, RosenblattLisa, YangLingfeng, SzwarcbergJavier

HIV treatment

Cobicistat and ritonavir are medications used to enhance the effectiveness of other antiretroviral drugs. This study compared the efficacy and safety of atazanavir combined with either cobicistat or ritonavir in HIV-infected adults.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

22.

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.

Author: DevredInès, KayembeKick, ValinNadia, RougierHayette, ShingaBruce Wuembulua, Lambert-NiclotSidonie, ChiarabiniThibault, MeyohasMarie-Caroline, LacombeKarine

HIV PEP

This study compares the completion rates of doravirine/tenofovir disoproxil fumarate/lamivudine (DOR/3TC/TDF) and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/c/FTC/TAF) for HIV post-exposure prophylaxis (PEP). The study found that DOR/3TC/TDF had a similar safety profile to EVG/c/FTC/TAF, with a comparable completion rate and no cases of seroconversion. DOR/3TC/TDF may be a cost-effective treatment option for PEP in the context of HIV-exposure accidents.

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

23.

Real-life cohort experience after implementing HIV pre-exposure prophylaxis for one year in northwest Spain.

Author: Pérez-GonzálezAlexandre, RepresaMarta, CollPep, PotelCarmen, Rodríguez-RiveroSilvia, FloresErene V, Vázquez-EstévezClaudia, OcampoAntonio, PousadaGuillermo, PovedaEva

HIV prevention

This study evaluated the effectiveness, safety, and adherence of PrEP (pre-exposure prophylaxis) in reducing HIV transmission in a real-world cohort in Northwest Spain. It also examined the impact of PrEP on sexually transmitted infections (STIs) and anal dysplasia rates.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

25.

Considerations regarding antiretroviral chemoprophylaxis in MSM.

Author: PoyntenI Mary, ZablotskaIryna, GrulichAndrew E

Prevents HIV transmission
Decreased bone mineral density
Risk compensation

Oral emtricitabine-tenofovir disoproxyl fumarate (TDF/FTC) is effective in preventing HIV infection among MSM. The protective effect is more than 90% with detectable levels of TDF or FTC in plasma and peripheral blood mononuclear cells.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

26.

Medical management of chronic liver diseases in children (part I): focus on curable or potentially curable diseases.

Author: El-ShabrawiMortada H F, KamalNaglaa M

Improved quality of life
Minimized liver damage
Gastrointestinal issues

This article focuses on managing potentially curable chronic liver diseases in children. Dietary changes are crucial for many conditions, and specific medications like nitisinone and copper-chelating agents are used for others. Antiviral therapies are also discussed for chronic viral hepatitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

27.

Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City.

Author: RaelChristine Tagliaferri, MartinezMichelle, GiguereRebecca, BocktingWalter, MacCrateCaitlin, MellmanWill, ValentePablo, GreeneGeorge J, ShermanSusan, FooterKatherine H A, D'AquilaRichard T, Carballo-DiéguezAlex

PrEP access
HIV/AIDS
PrEP side effects
Stigma

This study explored barriers and facilitators to PrEP use among transgender women in New York City. Barriers included side effects, stigma, and lack of research on transgender women and PrEP. Facilitators included smaller pill sizes and more research.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.